NeoGenomics, Inc. announced today an upcoming leadership team transition. William Bonello will be named Chief Financial Officer as of January 1, 2022.
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today an upcoming leadership team transition.
William Bonello will be named Chief Financial Officer as of January 1, 2022. Mr. Bonello currently serves as President of our Informatics Division. He has led the division since its inception in 2020, building the team out to over 60 people today and presiding over impressive early growth. Prior to that role, Mr. Bonello served as Chief Strategy and Corporate Development Officer helping to formulate the company’s growth strategy, and previously also served as Director of Investor Relations. Prior to joining NeoGenomics, Mr. Bonello worked as a healthcare equity analyst covering diagnostic services and product stocks at Craig-Hallum and at a variety of other investment banking firms and was also Senior Vice President for Investor Relations at LabCorp. Mr. Bonello received his B.A. degree from Carleton College and his MBA from the Kellogg School of Management at Northwestern University.
Kathryn McKenzie will be named Chief Sustainability and Risk Officer as of January 1, 2022. Ms. McKenzie currently serves as our Chief Financial Officer and has led the company through multiple acquisitions, financing events, and navigated the company through the financial challenges associated with the COVID-19 global pandemic. Prior to that role, Ms. McKenzie served as Vice President of Finance and Chief Accounting Officer. Before joining NeoGenomics, Ms. McKenzie served in various roles at Chico’s FAS, including Assistant Controller and Director of Financial Reporting and Treasury, and at Ernst and Young LLP. Ms. McKenzie is a Certified Public Accountant and holds a Master’s of Science in Accountancy from the University of North Carolina Wilmington.
“We are very excited to announce new appointments for two of our talented executives that positions the company for further success. We are delighted to name Bill as Chief Financial Officer and believe that his extensive capital markets and financial analysis background will be invaluable as we continue to execute on our ambitious growth strategy. We are also pleased to have Kathryn now serve in the newly created role of Chief Sustainability and Risk Officer with oversight of our Environmental, Social, and Governance initiatives as well as risk management activities,” said Mark Mallon, Chief Executive Officer of NeoGenomics.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to all relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to ensure the data we maintain is secured at all times.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories in Fort Myers and Tampa, Florida; Aliso Viejo, Carlsbad and San Diego, California; Research Triangle Park, North Carolina; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; and CAP accredited laboratories in Cambridge, United Kingdom; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia.
Forward-Looking Statements
Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “would,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” “plan,” “potential” and other words of similar meaning. These forward-looking statements address various matters including management transitions in 2022. These forward looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of the Company’s ability to continue gaining new customers, respond to the effects of the COVID-19 outbreak, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2021, as such information has been updated in subsequent SEC filings. . As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. NeoGenomics routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.neogenomics.com. The Company encourages investors and potential investors to consult the NeoGenomics website regularly for important information about NeoGenomics.
Forward-looking statements speak only as of the date such statements are made (unless another date is indicated) and should not be relied upon as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.
For further information, please contact:
NeoGenomics, Inc.
Doug Brown
Chief Strategy and Corporate Development Officer
T: 239.768.0600 x2539
M: 704.236.2064
doug.brown@neogenomics.com
Charlie Eidson
Director, Investor Relations and Corporate Development
T: 239.768.0600 x2726
M: 952.221.8816
charlie.eidson@neogenomics.com
SOURCE: NeoGenomics, Inc.
View source version on accesswire.com:
https://www.accesswire.com/671121/NeoGenomics-Announces-Leadership-Team-Transition
